The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1 Articles uri icon

authors

  • CIOFFI, MICHELE
  • TRABULO, SARA M.
  • VALLESPINOS, MIREIA
  • RAJ, DEEPAK
  • KHEIR, TONY BOU
  • LIN, MENG-LAY
  • BEGUM, JULFA
  • BAKER, ANN-MARIE
  • AMGHEIB, ALA
  • SAIF, JAIMY
  • PEREZ, MANUEL
  • SORIANO, JOAQUIM
  • DESCO MENENDEZ, MANUEL
  • GOMEZ GAVIRO, MARIA VICTORIA
  • CUSSO MULA, LORENA
  • MEGÍAS, DIEGO
  • AICHER, ALEXANDRA
  • HEESCHEN, CHRISTOPHER

publication date

  • January 2017

start page

  • 21609

end page

  • 21625

issue

  • 13

volume

  • 8

Electronic International Standard Serial Number (EISSN)

  • 1949-2553

abstract

  • The stromal microenvironment controls response to injury and inflammation, and is also an important determinant of cancer cell behavior. However, our understanding of its modulation by miRNA (miR) and their respective targets is still sparse. Here, we identified the miR-25-93-106b cluster and two new target genes as critical drivers for metastasis and immune evasion of cancer cells. Using miR-25-93-106b knockout mice or antagomiRs, we demonstrated regulation of the production of the chemoattractant CXCL12 controlling bone marrow metastasis. Moreover, we identified the immune checkpoint PD-L1 (CD274) as a novel miR-93/106b target playing a central role in diminishing tumor immunity. Eventually, upregulation of miR-93 and miR-106b via miR-mimics or treatment with an epigenetic reader domain (BET) inhibitor resulted in diminished expression of CXCL12 and PD-L1. These data suggest a potential new therapeutic rationale for use of BET inhibitors for dual targeting of cancers with strong immunosuppressive and metastatic phenotypes.

subjects

  • Biology and Biomedicine
  • Chemistry
  • Industrial Engineering
  • Medicine
  • Pharmacy
  • Telecommunications

keywords

  • metastasis; cd274; bone marrow; stromal niche; mdsc